Lymphoma Working Party (LWP)
Type d'étude:
Numéro de l'étude:
2019-R-05
Type de traitement à base de cellules souches:
Allogeneic - Unrelated
Maladies:
Titre court:
ATG vs PT-Cy in 1 MMUD
Objectif principal:
To retrospectively analyze outcomes after first allogenic hematopoietic stem cell transplantation (HSCT) from MMUD 9/10 with a reduced intensity conditioning (RIC) regimen comparing outcomes of PT-CY versus ATG as GVHD prophylaxis in patients with lymphoproliferative disorders
Principaux critères d'inclusion:
Inclusion criteria:
-Patients who received a 9/10 HSCT
-First HSCT (previous autologous transplantation accepted)
-High-resolution HLA allele typing at loci A, B, C, DRB1 and DQ available
-Stem Cell source (bone marrow or peripheral blood stem cells)
-Year of HSCT from 2010 to 2018
-All type of B and T cell lymphomas (NHL and HL, aggressive and indolent)
-All disease status at HSCT
-RIC regimen
-In vivo T cell depletion (TCD) with ATG (other in vivo TCD excluded) or PT-CY
Exclusion criteria:
-Cord Blood as stem cell source
-Other type of unrelated HSCT (matched unrelated, more than 1 mismatch)
-Patients who received a 9/10 HSCT
-First HSCT (previous autologous transplantation accepted)
-High-resolution HLA allele typing at loci A, B, C, DRB1 and DQ available
-Stem Cell source (bone marrow or peripheral blood stem cells)
-Year of HSCT from 2010 to 2018
-All type of B and T cell lymphomas (NHL and HL, aggressive and indolent)
-All disease status at HSCT
-RIC regimen
-In vivo T cell depletion (TCD) with ATG (other in vivo TCD excluded) or PT-CY
Exclusion criteria:
-Cord Blood as stem cell source
-Other type of unrelated HSCT (matched unrelated, more than 1 mismatch)
Pays:
Investigateur principal:
Annalisa Paviglianiti
Coordinateur EBMT de l'étude:
Hervé Finel
E-mail du coordinateur de l'étude:
herve.finel@upmc.fr